1849590-01-7 Usage
Description
EFT-508 is a potent inhibitor of MAPK interacting protein kinases (MNK) 1 and 2, with IC50s of less than 10 nanomolars. It effectively inhibits the phosphorylation of eukaryotic initiation factor 4E (eIF4E) with an IC50 value of less than 50 nanomolars in cellular signaling assays. EFT-508 has a half-life of 5.3 hours in rats, making it a promising compound for various applications.
Uses
Used in Pharmaceutical Industry:
EFT-508 is used as an inhibitor for immune checkpoint modulators due to its potent, highly selective, and orally bioavailable properties. It plays a crucial role in the study of inhibitors of immune checkpoint modulators and related methods, potentially contributing to the development of novel therapeutic strategies for various diseases.
Used in Cancer Research:
EFT-508 is used as a potent inhibitor of MNK1 and MNK2 in cancer research. By inhibiting these protein kinases, EFT-508 can potentially disrupt the signaling pathways involved in cancer cell growth and proliferation, offering a new avenue for cancer treatment development.
Used in Cellular Signaling Studies:
EFT-508 is used as a research tool for studying the phosphorylation of eIF4E in cellular signaling assays. Its ability to inhibit this process with high selectivity and potency makes it a valuable compound for understanding the underlying mechanisms of cellular signaling and the role of eIF4E in various biological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1849590-01-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,4,9,5,9 and 0 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1849590-01:
(9*1)+(8*8)+(7*4)+(6*9)+(5*5)+(4*9)+(3*0)+(2*0)+(1*1)=217
217 % 10 = 7
So 1849590-01-7 is a valid CAS Registry Number.
1849590-01-7Relevant articles and documents
CRYSTALLINE FORMS OF MNK INHIBITORS
-
Paragraph 0095; 0099-0100, (2020/05/14)
The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
